WASHINGTON — The Trump administration is turning to an unconventional approach to lowering drug prices in the United States: striking deals directly with big pharma companies in an attempt to bring U.S. prices in line with what other countries pay.

Trump and the nation’s health care officials have touted these “most-favored nation” deals as the most effective means to getting pharmaceutical prices down, beyond even the power of the Medicare drug price negotiations already in place. ×

This page requires Javascript.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings. kAm%96 <6J :DDF6[ 962=E9 6IA6CED D2J[ :D E92E E96 AF3=:4 92D 925 =:EE=6 G:D:3:=:EJ :?E@ E96D6 562=D]k^Am kAm“%96 92C5 A2CE[ @7 4@FCD6[ :D H6 5@?’E <?@H 6I24E=J H

See Full Page